Farideh Miraki‐Moud

2.0k total citations
33 papers, 1.4k citations indexed

About

Farideh Miraki‐Moud is a scholar working on Endocrinology, Diabetes and Metabolism, Hematology and Molecular Biology. According to data from OpenAlex, Farideh Miraki‐Moud has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Farideh Miraki‐Moud's work include Growth Hormone and Insulin-like Growth Factors (15 papers), Acute Myeloid Leukemia Research (9 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Farideh Miraki‐Moud is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (15 papers), Acute Myeloid Leukemia Research (9 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Farideh Miraki‐Moud collaborates with scholars based in United Kingdom, United States and Italy. Farideh Miraki‐Moud's co-authors include John G. Gribben, David Taussig, Dominique Bonnet, Jamie Cavenagh, Heather Oakervee, Debra M. Lillington, Samir Agrawal, Cecilia Camacho‐Hübner, Fernando Anjos‐Afonso and Emmanuel Griessinger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Farideh Miraki‐Moud

32 papers receiving 1.4k citations

Peers

Countries citing papers authored by Farideh Miraki‐Moud

Since Specialization

Citations

This map shows the geographic impact of Farideh Miraki‐Moud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farideh Miraki‐Moud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farideh Miraki‐Moud more than expected).

Fields of papers citing papers by Farideh Miraki‐Moud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farideh Miraki‐Moud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farideh Miraki‐Moud. The network helps show where Farideh Miraki‐Moud may publish in the future.

Co-authorship network of co-authors of Farideh Miraki‐Moud

This figure shows the co-authorship network connecting the top 25 collaborators of Farideh Miraki‐Moud. A scholar is included among the top collaborators of Farideh Miraki‐Moud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farideh Miraki‐Moud. Farideh Miraki‐Moud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phosphoproteomics identifies determinants of PAK inhibitor sensitivity in leukaemia cells 2025 ·Cell Communication and Signaling ·Pedro Casado, (unknown), (unknown), (unknown), Sandra M. Martín‐Guerrero, Farideh Miraki‐Moud, Vinothini Rajeeve, Pedro R. Cutillas	1
2	Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes 2023 ·Signal Transduction and Targeted Therapy ·Pedro Casado, Ana Rio‐Machín, Juho J. Miettinen, Findlay Bewicke‐Copley, Kevin Rouault‐Pierre, (unknown), Alun Parsons, Vinothini Rajeeve, Farideh Miraki‐Moud, David Taussig, Csaba Bödör, John G. Gribben, Caroline A. Heckman, Jude Fitzgibbon, Pedro R. Cutillas	13
3	Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T 2021 ·Blood ·(unknown), Leena Halim, Farideh Miraki‐Moud, David Taussig, John S. Bomalaski, John Maher, John G. Gribben, Peter W. Szlosarek, (unknown)	0
4	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736 2020 ·Blood Advances ·Andrew S. Moore, Amir Faisal, Grace Wing-Yan Mak, Farideh Miraki‐Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, (unknown), Andrew D.J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David Taussig, Spiros Linardopoulos	20
5	Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function 2020 ·Journal of Biological Chemistry ·Essam Ghazaly, Farideh Miraki‐Moud, (unknown), (unknown), (unknown), (unknown), (unknown), Robert Petty, Janet Matthews, (unknown), Simon P. Joel, Bryan D. Young, John G. Gribben, David Taussig	7
6	Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia 2020 ·Journal of Clinical Investigation ·Alexander Waclawiczek, Ashley Hamilton, Kevin Rouault‐Pierre, Ander Abarrategi, Manuel Garcia‐Albornoz, Farideh Miraki‐Moud, Nourdine Bah, John G. Gribben, Jude Fitzgibbon, David Taussig, Dominique Bonnet	49
7	A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery 2019 ·Pain ·Theresa Wodehouse, (unknown), Robert Petty, Farideh Miraki‐Moud, (unknown), (unknown), (unknown), (unknown), A. Oksche, Vivek Mehta, John G. Gribben, Richard Langford	15
8	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells 2018 ·Leukemia ·Pedro Casado, Edmund H. Wilkes, Farideh Miraki‐Moud, (unknown), Ana Rio‐Machín, Vinothini Rajeeve, (unknown), Sameena Iqbal, (unknown), Nicholas Lea, Steven Best, John G. Gribben, Jude Fitzgibbon, Pedro R. Cutillas	34
9	Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation 2013 ·Proceedings of the National Academy of Sciences ·Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Katharine Hodby, Emmanuel Griessinger, Guglielmo Rosignoli, Debra M. Lillington, Li Jia, Jeff Davies, Jamie Cavenagh, Matthew L. Smith, Heather Oakervee, Samir Agrawal, John G. Gribben, Dominique Bonnet, David Taussig	108
10	Acid-Labile Subunit Deficiency and Growth Failure: Description of Two Novel Cases 2010 ·Hormone Research in Paediatrics ·Alessia David, Stephen Rose, Farideh Miraki‐Moud, Louise Metherell, Martin O. Savage, Adrian Clark, C Camacho-Hübner	24
11	Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells 2008 ·Blood ·David Taussig, Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Daniel J. Pearce, Kirsty Allen, Christopher M. Ridler, Debra M. Lillington, Heather Oakervee, Jamie Cavenagh, Samir Agrawal, T. Andrew Lister, John G. Gribben, Dominique Bonnet	278
12	Final Height in Patients with Idiopathic Short Stature and High Growth Hormone Responses to Stimulation Tests 2006 ·Hormone Research in Paediatrics ·Carlos Eduardo Martinelli, (unknown), (unknown), (unknown), (unknown), Farideh Miraki‐Moud, (unknown), Ayrton Custódio Moreira, Martin O. Savage, Cecilia Camacho‐Hübner	6
13	Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement 2006 ·Clinical Endocrinology ·Antonia Brooke, (unknown), Farideh Miraki‐Moud, (unknown), (unknown), Dorothy Walker, J. P. Hinson, John P. Monson	18
14	Pseudo-precocious Puberty Caused by a Juvenile Granulosa Cell Tumour Secreting Androstenedione, Inhibin and Insulin-like Growth Factor-I 2004 ·Journal of Pediatric Endocrinology and Metabolism ·Li F. Chan, Helen L. Storr, Irene Scheimberg, L. A. Perry, Kaberi Banerjee, Farideh Miraki‐Moud, C Camacho-Hübner, M O Savage	6
15	Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells 2003 ·Journal of Endocrinology ·Maria Elisabeth Street, Farideh Miraki‐Moud, Ian R. Sanderson, M O Savage, G Giovannelli, Sergio Bernasconi, Cecilia Camacho‐Hübner	32
16	Effect of insulin-like growth factor binding protein-3 (IGFBP-3) on colon cancer epithelial cells growth and apoptosis 2002 ·Mansi A. Saksena, Farideh Miraki‐Moud, (unknown), C Camacho-Hübner	1
17	Increased levels of insulin‐like growth factor binding protein‐2 in sera and tumours from patients with colonic neoplasia with and without acromegaly 2001 ·Clinical Endocrinology ·Farideh Miraki‐Moud, Paul J. Jenkins, P D Fairclough, Suzanne Jordan, Stephen A. Bustin, Alison Jones, David Lowe, JP Monson, Ashley Grossman, G. M. Besser, Cecilia Camacho‐Hübner	28
18	Effect of Severe Growth Hormone (GH) Deficiency due to a Mutation in the GH-Releasing Hormone Receptor on Insulin-Like Growth Factors (IGFs), IGF-Binding Proteins, and Ternary Complex Formation Throughout Life1 1999 ·The Journal of Clinical Endocrinology & Metabolism ·Manuel H. Aguiar‐Oliveira, Matthew S. Gill, (unknown), Antônio Carlos Pereira Barretto, (unknown), Farideh Miraki‐Moud, (unknown), Anita H. O. Souza, Carlos Eduardo Martinelli, Fernanda Aparecida Castro Pereira, Roberto Salvatori, Michael A. Levine, Stephen M. Shalet, Cecilia Camacho‐Hübner, Peter Clayton	77
19	Insulin-like growth factor-I deficiency caused by a partial deletion of the IGF-I gene: Effects of rhIGFmi therapy 1999 ·Growth Hormone & IGF Research ·Cecilia Camacho‐Hübner, Katie A. Woods, Farideh Miraki‐Moud, (unknown), Martin O. Savage	6
20	Insulin-like growth factor binding protein-2 (IGFBP-2) levels are elevated in patients with acromegaly and colonic neoplasia 1998 ·Growth Hormone & IGF Research ·Farideh Miraki‐Moud, P Jenkins, P D Fairclough, (unknown), JP Monson, G. M. Besser, Cecilia Camacho‐Hübner	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact